DDInter927 DDInter170
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866]
Bedaquiline {u} (Compound) resembles {v} (Compound) Bromodiphenhydramine
Bedaquiline {u} (Compound) resembles {v} (Compound) Orphenadrine
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
Bedaquiline {u} (Compound) is included by {v} (Pharmacologic Class) Diarylquinolines
Bedaquiline {u} (Compound) causes {v} (Side Effect) Arrhythmia
Bedaquiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Bedaquiline (Compound) resembles Bromodiphenhydramine (Compound)
Bedaquiline (Compound) resembles Orphenadrine (Compound)
Bedaquiline (Compound) binds CYP3A4 (Gene)
Bedaquiline (Compound) is included by Diarylquinolines (Pharmacologic Class)
Bedaquiline (Compound) causes Arrhythmia (Side Effect)
Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Bedaquiline may lead to a major life threatening interaction when taken with Clarithromycin
Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib